Cervicovaginal HIV-1 shedding in women taking antiretroviral therapy in burkina faso: A longitudinal study

Journal of Acquired Immune Deficiency Syndromes

Volumn 65, Issue 2, 2014, Pages 237-245

  Low, Andrea J ^a   Konate, Issouf ^b   Nagot, Nicolas ^c,e   Weiss, Helen A ^a   Kania, Dramane ^b   Vickerman, Peter ^a   Segondy, Michel ^c,e   Mabey, David ^a   Pillay, Deenan ^d   Meda, Nicolas ^b   Van De Perre, Philippe ^c,e   Mayaud, Philippe ^a   Bahembera, Eloi ^b   Berthé, Abdramane ^b   Coulibaly, Minata ^b   Defer, Marie Christine ^b   Diallo, Ramata ^b   Djagbaré, Didier ^b   Huet, Charlotte ^b   Ky Dama, Florent ^b   M'Boutiki, Gilles T ^b   Millogo, Inès ^b   Ouédraogo, Abdoulaye ^b   Ouédraogo, Djénéba ^b   Rouet, Francois ^b   Sanon, Anselme ^b   Sawadogo, Haoua ^b   Vallo, Roselyne ^b   Vergne, Laurence ^b   Foulongne, Vincent ^e   Andonaba, Jean Baptiste ^f   Sawadogo, Adrien ^f   more..

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b CENTRE MURAZ   (Burkina Faso)

^c UMR 1058 University of Montpellier   (France)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIV MONTPELLIER   (France)

^f University Hospital of Bobo Dioulasso   (Burkina Faso)

Author keywords

Antiretrovirals; Bacterial vaginosis; Cervicovaginal lavage; Herpes simplex virus type 2; HIV 1 RNA; Nevirapine

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; EFAVIRENZ PLUS STAVUDINE PLUS LAMIVUDINE; INDINAVIR; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; MEDROXYPROGESTERONE ACETATE; NELFINAVIR; NEVIRAPINE; ORAL CONTRACEPTIVE AGENT; RITONAVIR; STAVUDINE; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; BURKINA FASO; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GENITAL SYSTEM EXAMINATION; GENITAL ULCER; GONORRHEA; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIMIT OF DETECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; PRIORITY JOURNAL; TREATMENT DURATION; UTERINE CERVIX; VAGINA; VAGINA DISCHARGE; VAGINAL LAVAGE; VAGINITIS; VIRUS DETECTION; VIRUS LOAD; VIRUS SHEDDING;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BURKINA FASO; COHORT STUDIES; FEMALE; GENITALIA, FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PLASMA; RISK FACTORS; RNA, VIRAL; VIRAL LOAD; VIRUS SHEDDING; YOUNG ADULT;

EID: 84893772783     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000049     Document Type: Article

References (55)

1. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005;191:1403-1409.
2. Modjarrad K, Chamot E, Vermund SH. Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS. 2008;22:2179-2185.
3. Lingappa JR, Hughes JP, Wang RS, et al. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One. 2010;5:e12598.
4. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001;357:1149-1153.
5. Baeten JM, Kahle E, Lingappa JR, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med. 2011;3:77ra29.
6. Sturmer M, Doerr HW, Berger A, et al. Is transmission of HIV-1 in nonviraemic serodiscordant couples possible? Antivir Ther. 2008;13:729-732.
7. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375:2092-2098.
8. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
9. Attia S, Egger M, MullerM, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23:1397-1404.
10. Chuachoowong R, Shaffer N, Siriwasin W, et al. Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. Bangkok Collaborative Perinatal HIV Transmission Study Group. J Infect Dis. 2000;181: 99-106.
11. Kovacs A, Wasserman SS, Burns D, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet. 2001;358:1593-1601.
12. Cu-Uvin S, Snyder B, Harwell JI, et al. Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months. J Acquir Immune Defic Syndr. 2006;42:584-587.
13. Tanton C, Weiss HA, Le Goff J, et al. Correlates of HIV-1 genital shedding in Tanzanian women. PLoS One. 2011;6:e17480.
14. Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. Sex Transm Dis. 2008;35:946-959.
15. Graham SM, Holte SE, Dragavon JA, et al. HIV-1 RNA may decline more slowly in semen than in blood following initiation of efavirenzbased antiretroviral therapy. PLoS One. 2012;7:e43086.
16. Graham SM, Holte SE, Peshu NM, et al. Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS. 2007;21:501-507.
17. Graham SM, Masese L, Gitau R, et al. Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment. J Infect Dis. 2010; 202:1538-1542.
18. Lambert-Niclot S, Tubiana R, Beaudoux C, et al. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002-2011 survey. AIDS. 2012;26: 971-975.
19. Cu-Uvin S, DeLong AK, Venkatesh KK, et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS. 2010;24:2489-2497.
20. Politch JA, Mayer KH, Welles SL, et al. Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men. AIDS. 2012;26:1535-1543.
21. Tanton C, Weiss HA, LeGoff J, et al. Patterns of herpes simplex virus shedding over 1 month and the impact of acyclovir and HIV in HSV-2- seropositive women in Tanzania. Sex Transm Infect. 2011;87:406-411.
22. Stall R, Duran L, Wisniewski SR, et al. Running in place: implications of HIV incidence estimates among urban men who have sex with men in the United States and other industrialized countries. AIDS Behav. 2009;13: 615-629.
23. Jia Z, Ruan Y, Li Q, et al. Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study. Lancet. 2012;382:1195-1203.
24. Nagot N, Ouangre A, Ouedraogo A, et al. Spectrum of commercial sex activity in Burkina Faso: classification model and risk of exposure to HIV. J Acquir Immune Defic Syndr. 2002;29:517-521.
25. Low AJ, Clayton T, Konate I, et al. Genital warts and infection with human immunodeficiency virus in high-risk women in Burkina Faso: a longitudinal study. BMC Infect Dis. 2011;11:20.
26. Huet C, Ouedraogo A, Konate I, et al. Long term virological, immunological and mortality outcomes in a cohort of HIV-infected female sex workers treated with highly active antiretroviral therapy in Africa. BMC Public Health. 2011;11:700.
27. World Health Organization. Dept. of HIV/AIDS, Interim WHO Antiretroviral Treatment Working Group. Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Guidelines for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2002.
28. Konate I, Traore L, Ouedraogo A, et al. Linking HIV prevention and care for community interventions among high-risk women in Burkina Faso - the ARNS 1222 "Yerelon" cohort. J Acquir Immune Defic Syndr. 2011; 57(suppl 1):S50-S54.
29. Nagot N, Foulongne V, Becquart P, et al. Longitudinal assessment of HIV-1 and HSV-2 shedding in the genital tract of West African women. J Acquir Immune Defic Syndr. 2005;39:632-634.
30. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991;29:297-301.
31. Rouet F, Foulongne V, Viljoen J, et al. Comparison of the Generic HIV Viral Load assay with the Amplicor HIV-1 monitor v1.5 and Nuclisens HIV-1 EasyQ v1.2 techniques for plasma HIV-1 RNA quantitation of non-B subtypes: the Kesho Bora preparatory study. J Virol Methods. 2010;163:253-257.
32. Burrows J, Nitsche A, Bayly B, et al. Detection and subtyping of Herpes simplex virus in clinical samples by LightCycler PCR, enzyme immunoassay and cell culture. BMC Microbiol. 2002;2:12.
33. Chomont N, Gresenguet G, Levy M, et al. Detection of Y chromosome DNA as evidence of semen in cervicovaginal secretions of sexually active women. Clin Diagn Lab Immunol. 2001;8:955-958.
34. Kwara A, Delong A, Rezk N, et al. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis. 2008;46:719-725.
35. Dumond JB, Yeh RF, Patterson KB, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS. 2007;21:1899-1907.
36. Else LJ, Taylor S, Back DJ, et al. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16:1149-1167.
37. Sheth PM, Kovacs C, Kemal KS, et al. Persistent HIV RNA shedding in semen despite effective antiretroviral therapy. AIDS. 2009;23:2050-2054.
38. Marcelin AG, Tubiana R, Lambert-Niclot S, et al. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma. AIDS. 2008;22:1677-1679.
39. Legoff J, Tanton C, Lecerf M, et al. Influence of storage temperature on the stability of HIV-1 RNA and HSV-2 DNA in cervicovaginal secretions collected by vaginal washing. J Virol Methods. 2006;138:196-200.
40. Tang MW, Kanki PJ, Shafer RW. A review of the virological efficacy of the 4 world health organization-recommended tenofovir-containing regimens for initial HIV therapy. Clin Infect Dis. 2012;54:862-875.
41. Lowenthal ED, Ellenberg JH, Machine E, et al. Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children. JAMA. 2013; 309:1803-1809.
42. Pillay P, Ford N, Shubber Z, et al. Outcomes for efavirenz versus nevirapinecontaining regimens for treatment of HIV-1 infection: a systematic review and meta-analysis. PLoS One. 2013;8:e68995.
43. Henning TR, Kissinger P, Lacour N, et al. Elevated cervical white blood cell infiltrate is associated with genital HIV detection in a longitudinal cohort of antiretroviral therapy-adherent women. J Infect Dis. 2010;202: 1543-1552.
44. Gitau RW, Graham SM, Masese LN, et al. Effect of acquisition and treatment of cervical infections on HIV-1 shedding in women on antiretroviral therapy. AIDS. 2010;24:2733-2737.
45. LeGoff J, Weiss HA, Gresenguet G, et al. Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes. AIDS. 2007;21:1569-1578.
46. Rebbapragada A, Wachihi C, Pettengell C, et al. Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS. 2007;21:589-598.
47. Freeman EE, Orroth KK, White RG, et al. Proportion of new HIV infections attributable to herpes simplex 2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics. Sex Transm Infect. 2007;83(suppl 1):i17-i24.
48. Hayes RJ, Schulz KF, Plummer FA. The cofactor effect of genital ulcers on the per-exposure risk of HIV transmission in sub-Saharan Africa. J Trop Med Hyg. 1995;98:1-8.
49. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010;362:427-439.
50. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med. 2008;358:1560-1571.
51. Legoff J, Bouhlal H, Gresenguet G, et al. Real-time PCR quantification of genital shedding of herpes simplex virus (HSV) and human immunodeficiency virus (HIV) in women coinfected with HSV and HIV. J Clin Microbiol. 2006;44:423-432.
52. Ouedraogo A, Nagot N, Vergne L, et al. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS. 2006;20:2305-2313.
53. Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis. 2012;12:19-26.
54. Baeten JM, Overbaugh J. Measuring the infectiousness of persons with HIV-1: opportunities for preventing sexual HIV-1 transmission. Curr HIV Res. 2003;1:69-86.
55. Larke NL, Weiss HA, Mayaud P, et al. Design of epidemiological studies measuring genital and plasma HIV-1 outcomes: lessons from a randomised controlled trial. Trop Med Int Health. 2009;14:267-275.